Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$19.86 From HK$18.36, Keeps at Neutral

MT NewswiresMar 24 05:05 ET · Ratings

Hansoh Pharmaceutical's 2024 Profit Jumps 33%

MT NewswiresMar 24 04:28 ET

UBS Group: Raised the Target Price of HANSOH PHARMA (03692) to HKD 24. Management anticipates that the contribution from Innovative Drugs will account for over 80%.

The management's goal for this year is to achieve sales of 6 billion yuan for Ameile, benefiting from the expansion of indications and supportive combination use scenarios; it is estimated that Ameile's peak sales may reach 8 billion yuan.

Zhitong FinanceMar 24 03:37 ET

[Brokerage Focus] CMB International maintains a Buy rating on HANSOH PHARMA (03692) as overseas licensing becomes a sustainable profit driver.

Jinwu Financial News | According to the research report from CMB International, HANSOH PHARMA (03692) will meet expectations in 2024, achieving revenue of 12.26 billion yuan (a year-on-year increase of 21.3%) and a net income of 4.37 billion yuan (a year-on-year increase of 33.4%). Product sales revenue reached 10.69 billion yuan (a year-on-year increase of 13.7%). Sales revenue from Innovative Drugs (excluding collaboration income) increased by 28.2% year-on-year, reaching 7.9 billion yuan. The bank expects the company to achieve the goal of Innovative Drugs sales revenue exceeding 10 billion yuan in 2025 (a year-on-year increase of over 25%). The company has improved cost efficiency in 2024.

Jingu Finance NewsMar 24 01:49 ET

The Hong Kong stock market is restructuring the value of pharmaceuticals! Hengrui Medicine has received a premium binding from AstraZeneca, and the stock price once rose over 20%.

① Does the offshore strategy mean that "technology platform premium + international certification" is replacing the traditional PE valuation method as the core logic for valuing Innovative Drugs companies? ② With JACOBIO-B narrowing its annual loss by 56.6% through its core product Galidesivir, can it be inferred that China’s Innovative Drugs companies have broken through the industry curse of "burning money on R&D - ongoing losses"?

cls.cnMar 23 22:56 ET

Hong Kong stock movement | HANSOH PHARMA (03692) rises over 4% after earnings, with annual shareholder profits increasing by over 30% year-on-year, and Amerland sales rapidly expanding.

HANSOH PHARMA (03692) surged over 4% after the performance announcement, as of press time, up 4.48%, priced at 21 Hong Kong dollars, with a transaction volume of 73.9313 million Hong Kong dollars.

Zhitong FinanceMar 23 22:29 ET